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Summary.-A control series of 105 patients in hospital with non-malignant diseases
was used in a limited clinical assessment of the MOD-MEM test. Twenty-seven
positive results could be explained on the basis ofdestruction ofnervous parenchyma,
tissue necrosis, tuberculosis, malignant disease, etc. The remaining 13 unexplained
positives showed a sex and age distribution in agreement with that predicted from
cancer registration statistics if the MOD-MEM test detects cancer about 16 years
before the clinical appearance of the disease.
The Macrophage Electrophoretic
Mobility (MEM) test (Field and Caspary,
1970) can distinguish healthy control
subjects from patients who have malig-
nant disease with a remarkable absence of
overlap, a rare feature in a biologically
based test (Pritchard et al., 1972; Field,
Caspary and Smith, 1973; Preece and
Light, 1974). However, the acceptability
of an in vitro cancer test depends upon its
success in detecting malignant disease
against a wide spectrum of advanced or
chronic non-malignant conditions. When
tested in this way, many claims for
diagnostic cancer tests have not been
substantiated. It has already been shown
(Field, 1973) that diseases such as sarcoi-
dosis, Crohn's disease, ulcerative colitis,
intrinsic asthma, myasthenia gravis and
certain neurological conditions can pro-
duce lymphocyte sensitization to myelin
basic protein (MBP), the antigen used to
elicit the response in the MEM test and
its derivative MOD-MEM (Pritchard et
al., 1973a). This paper presents the
results of a study undertaken to assess the
performance of the MOD-MEM test in
distinguishing cancer subjects from a
control series ofpatients hospitalized with
non-malignant diseases.
MATERIALS AND METHODS
Lymphocyte preparation and the produc-
tion of guinea-pig macrophages have been
described elsewhere (Pritchard et al., 1973b).
Because the test material for this investi-
gation was obtained from a general hospital
at a considerable distance from the base
laboratory, defibrinated blood samples pre-
pared immediately after venipuncture were
stored at 4°C overnight in tissue culture
medium 199 with 10% added autologous
serum. Before use in the MOD-MEM assay,
the cell suspensions were washed 3 times by
centrifugation at 350 g in TC 199 to ensure
removal of serum constituents. Aliquots
containing 106 lymphocytes in 3 ml were then
incubated with 100 ,ug of MBP under the
split incubation conditions ofthe MOD-MEM
test (Pritchard et al., 1973b). Electrophoretic
mobility determinations were made in a
modified Zeiss cytopherometer, using a
current of 9-5 mA at 190 V. The sinter-
containing glass spacers of the normal Zeiss
electrode assemblies were replaced by perspex
spacers without sintered discs, but fitted with
captive 'O' rings at each end to improve
performance by eliminating drift due to
microleakage of electrolyte. Residual drift
was cancelled by careful adjustment of small
clamps on the entry and exit tubes to the
measurement chamber. For each sample, 10
pairs of timings were made of macrophages
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selected by size (16 ,um) and containing 2 or 3
oil droplets (Shenton, Hughes and Field,
1973). The double column system of
recording results (Pritchard et al., 1972,
1973a and 1973b) was not used for this series
owing to the possibility of transient or early
sensitization, indicated by small percentage
changes in macrophage mobilities.
Measurements were made double-blind, with
neither the identity of the blood donor, nor
the presence or absence of antigen in the
sample, being known to the operator.
Samples from subjects with cancer were
introduced at random to maintain a check on
the test protocol.
RESULTS
Diseases listed in Table I did not give
MOD-MEM results within the positive
range (that is, a reduction of at least 80%
in macrophage electrophoretic mobility
from the normal value). One of the
difficulties associated with this investi-
gation is the possibility that patients may
previously have had a disease which,
although cured, causes a persistent
lymphocyte sensitization which still gives
rise to a MOD-MEM+ result. This is
illustrated by the group of hypertensive
subjects where 2 out of 6 gave positive
results. Analysis of their past medical
histories revealed that one had suffered a
cerebrovascular attack and the other had
suffered a subarachnoid haemorrhage 6
months before admission for hypertensive
care. Both of these conditions are
associated with degeneration of nerve
tissue, and lymphocyte sensitization to
myelin basic protein can be expected
(Field, 1973). The frequent occurrence of
such examples in an investigation of this
nature makes a clear demarcation between
disease groups difficult. One out of 5
asthmatic subjects gave a positive result.
Clinical evidence suggested that this
particular patient (Table II) was suffering
from intrinsic asthma, which has been
shown to give MEM+ results (Caspary,
Feinman and Field, 1973). The other 4
asthma cases (Table I) were clinically
classified as extrinsic asthma.
Results within the positive range were
found for the diseases listed in Table II.
In most of these groups, lymphocyte
sensitization could be attributed to
destruction of nervous parenchyma, tissue
necrosis or malignancy. Positive results
TABLE I.-Cases with MOD-MEM Percentage Slowing <6°% (MOD-MEM-)
Disease
Chronic inflammatory pelvic mass
Pyrexia, unknown origin
Pulmonary embolus
Pernicious anaemia
Rectal polyp
Surgical cases: Tonsilitis
Varicose veins
Appendix
Right inguinal hernia
Pilonidal sinus
Breast lumps later proved non-malignant
Hypertension
Menorrhagia
Pregnancy (at different stages)
Severe headache
Generalized arteriosclerosis
Attempted suicide (Barbiturates)
Chronic pyelonephritis
Asthma (extrinsic)
Thyrotoxicosis
Cholecystitis
Rheumatoid arthritis
No. of %
cases slowing
1 0
1
2
1
1
1
2
4
2
5
1
2
1
3
4
7
4
3
J
0
1.0
<1-3
1 *5
<1-6
<2*3
<2-7
<3*0
<3 0
3-5
<3.8
4 0
<4 0
<4 0
<4 0
<4*5
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TABLE II.-Cases with MOD-MEM Per-
centage Slowing >8% (MOD-MEM+)
Disease
Collagen disease+arthritis
Farmer's lung
Diabetes+Crohn's disease
Trigeminal neuralgia
Hypertension+history of C.V.A.
Asthma (intrinsic)
Liver cirrhosis and ascites
Multiple sclerosis
Hypertension+history of
subarachnoid haemorrhage
Subacute degeneration of cord
Cerebral arteriosclerosis and
gangrene (both legs)
Subarachnoid haemorrhage
Mitral valve disease+rheumatism
+glomerulonephritis
Cerebrovascular attack
Pneumonia
Pulmonary tuberculosis
Breast lumps-later proved
malignant
Malignant disease
from patients with pulmoi
culosis would be expected,
been shown (Field, Casparn
1963; McDermott, Caspary an
1974) that MBP shares anti
minants with PPD. The
presenting with breast lumps i
value of the MOD-MEM
clinical diagnosis of malign
Four of the 6 gave posi
(Table II) and biopsysubsequ4
the presence of malignant d
remaining 2 subjects with n
results (Table I) showed no la
of malignancy.
Table III lists the diseas
mixed results for the same
unexpected results which c(
explained at the time of tl
therefore could not be placec
dence in Tables I or II. St
positive results in Table IIL
continuing clinical review.
follow-up, 9 months after the i
the patient listed as sufl
dysphagia (Table III) was fo
carcinoma of the oesophagus
not apparent at the time oi
MEM test.
No.
of
cases
I
1
1
1
1 1
1
1
1
1 1
I
4
4
2
slowing
11 0
13-0
13 8
14X0
14X0
16X4
17-0
18-0
19-2
21*0
21*0
21 7
24'7
8-0-20 0
14 0-21 0
15*0-16 0
TABLE III.-Cases with Mixed Results
Requiring Follow-up
No. of %
Disease cases slowing
Pigmented moles 1 1-8
1 15-0
Rheumatic fever 1 1.0
Diabetes
Diabetes+enlarged liver
Duodenal ulcers
Chronic bronchitis
Myocardial infarction
Dysphagia (see text)
l 9.0
2 <4 0
1 22*5
1 16 8
4 <3-2
4 13'0-16'0
2 <2-0
3 13-0-2040
6 <6-0
1 22*6
1 18.0
DISCUSSION
4 110 l 7" X It has been claimed that the MEM test
11 11i 1-23 0 is capable of detecting cancer many years
before the clinical appearance of the
nary tuber- disease (Field, Caspary and Shepherd,
since it has 1972; Caspary, Shepherd and Field, un-
y and Bell, pub.). The claim is based on the
dDickinson, detection of cancer-sensitized circulating
igenic deter- lymphocytes, assumed to be of maternal
6 subjects origin, in the blood of children born up to
illustrate the 12 years before the mothers presented
test in the with cancer. Although these findings
ant disease. require further substantiation, they raise
itive results the possibility that the whole 13 un-
entlyshowed explained positives for which no
isease. The explanation could be found at the time of
iegative test the test (Table III) may have been caused
tter evidence by pre-clinical malignant disease un-
detectable by other means. To check
es that gave this possibility, we have estimated the
disease, or approximate number of unexplained posi-
auld not be tives to be expected in the present series,
'e test, and using the registration rates for new
I with confi- cancers published in 'Cancer Registration
ubjects with in South Wales, 1963 to 1967'. With one
I are under year of 'early warning' the test should
At the first pick out all those individuals in the series
original test, who, although cancer-free at the time of
fering from the test, will appear as new cancer
und to have registrations one year later. With two
3. This was years of 'early warning' the number will
f the MOD- increase to the sum ofthose who will reach
registration one year and two years later,
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and so on. From graphs of the regis-
tration rates per 100,000 males or females,
plotted against age, it is possible in this
way to estimate the fractional contri-
bution to be expected from each male or
female individual in the actual series
towards the final total of unexplained
positives, assuming any specified number
of years of average 'early warning'.
For the purpose of this analysis, the
group of 6 patients in hospital for the
investigation of breast lumps were
excluded from the series, on the grounds
that they were a selected group already
under an unknown degree of 'high risk' for
malignant disease, and therefore not
subject to the 'normal' cancer registration
rates. Similarly, the first 23 patients
from Table II were excluded on the
grounds that any positive results due to
pre-clinical malignant disease in this
group would be masked by the fact that
their test results were already positive
from the conditions for which they were
hospitalized. The 11 malignant subjects
deliberately introduced as a check on the
operation of the test were not part of the
control series, leaving a final group of 38
males and 38 females available for the
estimation of unexplained positive rates
due to possible pre-clinical malignant
disease. The numbers in this final group
are too small for an adequate level of
statistical confidence in the result, and
therefore no attempt has been made to
correct for secondary factors. These
factors can be expected to reduce the
accuracy of the prediction mainly for
stibjects of advanced age. The South
Wales cancer registration rates for 1963-67
represent the most relevant data available
for the control series under study, but are
now known to have been too low in the
years immediately following the establish-
ment of the registry. Therefore cor-
rections were applied to update the
figures to the year of the test, with a
further small estimated correction for the
rate of increase expected in the future.
A more detailed account of the derivation
of the unexplained positive rates to be
cn
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FIG.-Predicted and observed numbers and dis-
tribution of unexplained positives. For details see
text.
expected if the test detects preclinical
cancer will be published separately
(Sutherland, Pritchard and Smith).
The figure shows the numbers of
unexplained positives predicted for that
fraction of the 76 subjects above each
specified age, plotted (solid lines) for
'early warning' periods of 15, 16 and 17
years. The 13 positives from Table III
which could not be attributed to known
causes at the time of the test are plotted
as open circles. Although the sexes were
exactly balanced in the final group
(38M+38F), the large differences between
the cancer registration rates for males and
females result in quite different numbers
ofpredicted positives. The separate male
and female predictions for 16 years of
early warning are plotted (broken lines) in
the fig. The full circles (male) and
crosses (female) show the subdivision by
sex of the 13 observed unexplained
positives represented by the open circles.
CONCLUSIONS
The appearance of 13 unexplained
positives with the age and sex distribution
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shown in the Fig. is therefore not un-
expected in this control series. One ofthe
13 positives has already transferred into
the malignant category at the first 9
month follow-up. Our results emphasize
the extreme difficulty ofconducting defini-
tive tests on early detection techniques in
diseases such as cancer, where long latent
p3riods are possible and perhaps more
common than is generally realized.
The process of lymphocyte sensit-
ization, as measured by the MEM or
MOD-MEM test, is not specific to malig-
nant disease, at this stage in the
development of the techniques, but this
should not detract from the value of the
test as an adjunct to existing clinical
diagnostic procedures. The accumulated
experimental results from a number of
centres suggest that a MOD-MEM-result
has considerable diagnostic value in the
elimination of suspect malignant disease,
since the occurrence of false negatives is
extremely rare in those laboratories where
the test has been successfully established.
Lymphocyte sensitization may persist
for many years. This has been verified by
checking 10-year survivors from carci-
noma ofthe head and neck who, although
now clinically disease-free, still show
MOD-MEM results within the positive
range (Pritchard, Henk and Hart, unpub.).
Therefore, at the time ofthe test a patient
may be under investigation for a disease
which itself does not give rise to lympho-
cyte sensitization, but a positive result is
obtained due to a previous illness which
caused sensitization to the antigen under
study.
The test has been described as techni-
cally difficult toperform,butourexperience
has shown that the difficulties largely
disappear with rigid adherence to the
recommended principles and precautions
(Pritchard et al., 1973a, b; Goldstone,
Kerr and Irvine, 1973; Tognella et al.,
1974; Meyer-Rienecker et al., 1974).
Variations from therecommendedprotocol
can be evaluated only against a technique
already well established and working
successfully and consistently. Many of
the problems that have been encountered
during the development of the test can
now be attributed to the guinea-pig
macrophages used as indicator cells in the
bioassay. A sufficiently high standard of
animal husbandry will ensure that such
problems do not arise (Field and Shenton,
1975). Mass screening oflarge sections of
the general population for malignant
disease is not practical until a more
refined and automated technique has been
developed, together with a suitable back-
up system adapted for more specific
investigation andtumourlocalization.
We wish to thank Tenovus for contin-
ued generous financial support. We are
grateful to Mrs J. Morgan and Miss D.
Boyle for excellent technical assistance,
and to C. W. Smith and R. R. West for
help and advice. We are also indebted to
our consultant colleagues at Bridgend
General Hospital for access to clinical
material.
REFERENCES
CASPARY, E. A., FEINMAN, E. L. & FIELD, E. J.
(1973) Lymphocyte Sensitisation in Asthma with
Special Reference to Nature and Identity of
Intrinsic Form. Br. med. J., i, 15.
FIELD, E. J. (1973) Immunological Diagnosis of
Cancer. In Modern Trend8 in Oncology 1.
London: Butterworth. 183.
FIELD, E. J. & CASPARY, E. A. (1970) Lymphocyte
Sensitisation: an in -Vitro Test for Cancer? Lancet,
ii, 1337.
FIELD, E. J., CASPARY, E. A. & BALL, E. J. (1963)
Some Biological Properties of a Highly Active
Encephalitogenic Factor Isolated from Human
Brain. Lancet, ii, 11.
FIELD, E. J., CASPARY, E. A. & SHEPHERD, R. H. T.
(1972) Imrnunodiagnosis of Cancer. Br. med. J.,
iii, 641.
FIELD, E. J. & SHENTON, B. K. (1975) The Macro-
phage Electrophoretic Mobility (MEM) Test: A
Consideration of the Practical Difficulties and
Implications of the Method. I.R.C.S., Med.
Science, 3, 154.
FIELD, E. J., CASPARY, E. A. & SMITH, K. S. (1973)
Macrophage Electrophoretic Mobility (MEM) Test
in Cancer: A critical Evaluation. Br. J. Cancer,
28, Suppl. 1, 208.
GOLDSTONE, A. H., KERR, L. & IRVINE, W. J. (1973)
The Macrophage Electrophoretic Migration Test
in Cancer. Clin. exp. Immun., 14, 469.
MCDERMOTT, J. R., CASPARY, E. A. & DICKINSONN,
J. P. (1974) Antigen Cross Reactivity in the
Macrophage Electrophoretic Mobility Test. Clin.
exp. Immun., 17, 103.6 J. A. V. PRITCHARD, J. L. MOORE, W. H. SUTHERLAND AND C. A. F. JOSLIN
MEYER-RIENECKER, H., JENSSEN, H. L., KORLER,
H., GUNTHER, J. & GUNDLACH, H. J. (1974) Zur
Anwendung und Bedeutung des Makrophagen-
Elektrophorese-Mobilitas (MEM) Testes bei
neurologischen Erkrankungen. Klin. W8chr., 52,
288.
PREECE, A. W. & LIGHT, P. A. (1974) The Macro-
phage Electrophoretic Mobility (MEM) Test for
Malignant Disease. Clin. exp. Immun., 18, 543.
PRITCHARD, J. A. V., MOORE, J. L., SUTHERLAND,
W. H. & JOSLIN, C. A. F. (1972) Macrophage
Electrophoretic Mobility (MEM) Test for Malig-
nant Disease-an Independent Confirmation.
Lancet, ii, 627.
PRITCHARD, J. A. V., MOORE, J. L., SUTHERLAND,
W. H. & JOSLIN, C. A. F. (1973a) Technical
Aspects of the Macrophage Electrophoretic
Mobility (MEM) Test for Malignant Disease. Br.
J. Cancer, 28, Suppl. 1, 229.
PRITCHARD, J. A. V., MOORE, J. L., SUTHERLAND,
W. H. & JOSLIN, C. A. F. (1973b) Evaluation and
development of the Macrophage Electrophoretic
Mobility (MEM) Test for Malignant Disease.
Br. J. Cancer, 27, 1.
SHENTON, B. K., HUGHES, D. & FIELD, E. J. (1973)
Macrophage Electrophoretic Migration (MEM)
TestforLymphocyte Sensitization: SomePractical
Experiences in Macrophage Selection. Br. J.
Cancer, 28, Suppl. 1, 215.
ToGNELLA, S., MANTOVANI, G., FLORIS, C., CENGIA-
ROTTI, L., GIACCO, G. & GRIFONI, V. (1974) Test
Citoferometrico per L'evidenziazone di Linfociti
Sensibilizzati ad Antigeni Neoplastici (MEM) Test.
Tumori, 60, 203.